CRIS Current Research Information System

CASADEI, BEATRICE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 7.217
EU - Europa 6.519
NA - Nord America 5.861
Continente sconosciuto - Info sul continente non disponibili 366
SA - Sud America 360
AF - Africa 335
OC - Oceania 19
Totale 20.677
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.697
NL - Olanda 2.203
VN - Vietnam 1.872
SG - Singapore 1.824
CN - Cina 1.664
IT - Italia 1.395
DE - Germania 849
HK - Hong Kong 683
GB - Regno Unito 501
SE - Svezia 489
IN - India 276
BR - Brasile 260
FR - Francia 230
KR - Corea 222
RU - Federazione Russa 205
BD - Bangladesh 197
IE - Irlanda 133
FI - Finlandia 121
JP - Giappone 119
CI - Costa d'Avorio 109
UA - Ucraina 84
CA - Canada 83
ZA - Sudafrica 69
TG - Togo 54
AR - Argentina 50
TH - Thailandia 49
ID - Indonesia 46
PH - Filippine 46
PL - Polonia 45
AT - Austria 43
JO - Giordania 42
SC - Seychelles 41
ES - Italia 32
TR - Turchia 31
EE - Estonia 30
IQ - Iraq 29
NG - Nigeria 29
CH - Svizzera 28
MX - Messico 27
BE - Belgio 24
BG - Bulgaria 23
TW - Taiwan 23
AU - Australia 17
PK - Pakistan 17
CL - Cile 15
SA - Arabia Saudita 15
LT - Lituania 14
JM - Giamaica 13
EC - Ecuador 9
EG - Egitto 9
MY - Malesia 9
RO - Romania 9
CR - Costa Rica 8
PT - Portogallo 8
UZ - Uzbekistan 8
IR - Iran 7
PE - Perù 7
RS - Serbia 7
TT - Trinidad e Tobago 7
CZ - Repubblica Ceca 6
KE - Kenya 6
PR - Porto Rico 6
VE - Venezuela 6
BY - Bielorussia 5
DK - Danimarca 5
DO - Repubblica Dominicana 5
GR - Grecia 5
GT - Guatemala 5
IL - Israele 5
LB - Libano 5
PY - Paraguay 5
AE - Emirati Arabi Uniti 4
HR - Croazia 4
MD - Moldavia 4
MK - Macedonia 4
BO - Bolivia 3
CG - Congo 3
MA - Marocco 3
MM - Myanmar 3
OM - Oman 3
PS - Palestinian Territory 3
AL - Albania 2
AZ - Azerbaigian 2
CO - Colombia 2
DZ - Algeria 2
GE - Georgia 2
GH - Ghana 2
HU - Ungheria 2
IS - Islanda 2
LC - Santa Lucia 2
LV - Lettonia 2
NI - Nicaragua 2
NP - Nepal 2
NZ - Nuova Zelanda 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
UY - Uruguay 2
AF - Afghanistan, Repubblica islamica di 1
AG - Antigua e Barbuda 1
AM - Armenia 1
Totale 20.289
Salva come PNG Salva come JPEG
Città #
Singapore 1.322
Eygelshoven 1.286
Ashburn 715
Kerkrade 666
Hong Kong 635
Ho Chi Minh City 473
Hefei 452
San Jose 426
Hanoi 395
Frankfurt am Main 393
Fairfield 387
Southend 373
Santa Clara 332
Chandler 330
Bologna 296
Beijing 211
Seoul 210
Houston 193
Woodbridge 174
Seattle 170
Dong Ket 166
Council Bluffs 158
Wilmington 153
Milan 148
Boardman 145
Princeton 136
Ann Arbor 134
Dublin 133
Los Angeles 128
Cambridge 121
New York 115
Abidjan 109
Tokyo 91
Lauterbourg 90
Helsinki 86
Rome 77
Da Nang 73
Berlin 66
Haiphong 57
Dallas 54
Lomé 54
São Paulo 54
Buffalo 52
Bengaluru 46
Chicago 46
Redmond 43
Munich 42
Amman 41
Hyderabad 41
Kyiv 41
Nanjing 40
Guangzhou 38
Jinan 38
Westminster 38
The Dalles 37
Bremen 36
Turin 36
London 34
Redondo Beach 34
Falkenstein 33
Warsaw 32
Changsha 31
Padova 31
Amsterdam 30
San Diego 30
Lappeenranta 29
Brooklyn 28
Jakarta 28
Florence 27
Nuremberg 26
Shanghai 26
Düsseldorf 25
Phoenix 24
Shenyang 24
Abeokuta 23
Bangkok 23
Tianjin 23
Toronto 23
Biên Hòa 22
Modena 22
Verona 22
Bern 21
Brussels 21
Johannesburg 21
Hải Dương 20
Atlanta 19
Bến Tre 19
Des Moines 19
Orem 19
Rimini 19
Vienna 19
Can Tho 17
Secaucus 17
Sofia 17
Dearborn 16
Baghdad 15
Catania 15
Istanbul 15
Nanchang 15
Tongling 15
Totale 13.391
Salva come PNG Salva come JPEG
Nome #
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years 2.866
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience 471
CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cells 342
Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium 280
A case of pityriasis lichenoides et varioliformis acuta developed after first dose of Oxford-AstraZeneca COVID-19 vaccine 258
Metabolic profile evolution in relapsed/refractory B-cell non-Hodgkin lymphoma patients treated with CD19 chimeric antigen receptor T-cell therapy and implications in clinical outcome 258
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 254
Intracranial pressure management in fulminant cerebral oedema after CAR T-cell therapy: Not all is lost! 249
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 245
The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation 244
Peripheral blood cellular profile at pre-lymphodepletion is associated with {CD}19-targeted {CAR}-T cell-associated neurotoxicity 241
Is it really possible to cure hairy cell leukemia patients only with frontline therapy? 233
Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study 231
(90) Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study 228
Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue 227
Case report: Senescence as mechanism of resistance to Pembrolizumab in a Lymphoma patient who failed CD19-Targeted CAR-T cell therapy 224
The Berlin-Frankfurt-Münster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience 224
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 218
Efficacy and Safety of Frontline Single‐Agent Rituximab in Extranodal Marginal Zone Lymphoma 217
Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients 217
CAR t-cell therapy in BOlogNa–NEUrotoxicity TReatment and Assessment in Lymphoma (CARBON–NEUTRAL): proposed protocol and results from an Italian study 215
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma 213
Long-term responders after Brentuximab vedotin: Single-center experience on relapsed and refractory hodgkin lymphoma and anaplastic large cell lymphoma patients 208
Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity 206
The treatment of primary mediastinal large B-cell lymphoma: A two decades monocentric experience with 98 patients 203
PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series 195
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study 191
Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. 188
Follicular Lymphoma Microenvironment Traits Associated with Event-Free Survival 186
Hairy Cell Leukemia: Allogeneic Transplantation Could be an Optimal Option in Selected Patients. 185
Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study 184
Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation in Follicular Lymphoma. 182
The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients 182
Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma 180
Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors-The MicroLinf Study 178
Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients 177
A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies 177
Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. 175
Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice 175
Different definitions in intention-to-treat analysis for chimeric antigen receptor T-cell therapy depend on research scope 172
The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. 172
Histological findings in patients with suspected mediastinal lymphoma relapse according to positive positron emission tomography scan during follow-up: a large retrospective analysis in 96 patients 169
Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma 168
Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients 168
Management of central nervous system relapse in a young patient affected by primary mediastinal large B-cell lymphoma: A case report 164
Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy 163
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma). 162
Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series. 162
Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience 159
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 158
Interesting activity of pegylated liposomal doxorubicin in primary refractory and multirelapsed Hodgkin lymphoma patients: Bridge to transplant 157
Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports. 157
Vemurafenib mucosal side-effect. 155
The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience 151
Correction to: Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy 150
Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection 150
Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma. 149
Low doses ATLG as GvHD prophylaxis in allogeneic hematopoietic stem cell transplantation for lymphomas 148
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study 148
Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results 146
Outpatient experience with biosimilar filgrastim in patients with lymphoid neoplasm: Lessons from daily clinical practice 146
Successful Bridging to Allogeneic Transplantation With Valemetostat in Two Refractory/relapsed Peripheral T-cell lymphoma patients 144
Impressive Response to Pixantrone after Allogeneic Transplant in a Multiple Relapsed Diffuse Large B-Cell Lymphoma 144
Prospective Validation of CAR-HEMATOTOX and a Simplified Version Predict Survival in Patients with Large B-Cell Lymphoma Treated with Anti-CD19 CAR T-Cells: Data from CART-SIE Study 141
Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. 141
Ultrasound-guided core needle biopsy of nodular lesions of the spleen in hematology clinical practice 139
Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice 138
Erythroderma with brentuximab vedotin (skin side effects in mycosis fungoides) 138
Erythrodermie mit Brentuximab‐Vedotin (Hautnebenwirkungen bei Mycosis fungoides) 136
Impressive continuous complete response after mogamulizumab in a heavily pretreated Sézary syndrome patient 132
A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas 130
Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia 127
New therapies and old side-effects in mycosis fungoides treatment: brentuximab vedotin-induced alopecia 126
Prolonged responses to brentuximab vedotin as last therapy in Hodgkin lymphoma failing autologous transplantation: A case series 126
Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma 126
Long-term efficacy and safety of ibrutinib in the treatment of CLL patients: A real life experience 125
Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients. 123
Successful stem cell harvest and autologous transplantation in a patient with cold agglutinin syndrome and aggressive lymphoma 123
Elderly Non-GCB Diffuse Large B-Cell Lymphoma Patient Responding to Lenalidomide after Epicardial Relapse: A Case Report 123
Clinical Response in Heavily Pretreated Mycosis Fungoides with Pembrolizumab: A Case Report 123
SARS-CoV-2 infection does not affect the outcome of patients with relapsed/refractory large B-cell lymphoma treated with CAR T-cell therapy 120
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma 116
Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma 116
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 115
Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors 115
Frontal predominant encephalopathy with early paligraphia as a distinctive signature of CAR T-cell therapy-related neurotoxicity 113
The small molecule CHK1/CHK2 inhibitor PF-0477736 (Pfizer) demonstrates single agent activity in diffuse large B-cell lymphoma 112
Spontaneous remission of follicular lymphoma 111
NR1H3 (LXRα) is associated with pro-inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b-cell lymphoma 109
Allogeneic stem cell transplantation is capable of healing a case of bone marrow aplasia following CAR-T cell therapy in a lymphoma patient 107
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study 106
Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study 98
Fulminant cerebral edema following CAR T-cell therapy: case report and pathophysiological insights from literature review 95
Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma 94
Rapid but reversible progression and transformation of chronic lymphocytic leukemia after temporary ibrutinib discontinuation due to off-target toxicity: two interesting cases 92
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy 91
Pixantrone as bridging therapy to allogeneic transplantation or in chimeric antigen receptor T‐cell pathway in patients with diffuse large B‐cell lymphoma 88
Duvelisib as bridge to allotransplantation in refractory peripheral T-cell lymphoma with T-follicular helper phenotype: case report 87
TALOs, Fill the Gap: Tafasitamab and Lenalidomide in Diffuse Large B‐Cell Lymphoma in the Real‐Life Patient Journey 83
Follicular lymphoma: the diminishing role of chemotherapy. 82
Totale 19.356
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.960
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.960
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.105 0 56 59 106 97 62 23 93 44 118 270 177
2022/20231.678 142 223 117 202 124 125 55 138 260 53 129 110
2023/2024739 56 98 67 88 64 90 37 54 24 66 39 56
2024/20253.658 169 322 299 233 432 192 291 153 113 353 263 838
2025/202610.323 691 734 604 601 724 1.694 2.087 308 1.485 604 444 347
2026/2027602 330 272 0 0 0 0 0 0 0 0 0 0
Totale 20.677